In most cases, however, the primary androgen deprivation therapy is only transiently effective and prostate cancer progresses after a variable period of time to a status known as castration-resistant prostate cancer (CRPC) [8], for which several different therapeutic options are available, such as chemotherapy with cabazitaxel [9], inhibition of androgen receptor by abiraterone [10] and enzalutamide [11], sipuleucel‐T immunotherapy [12], radiotherapy with radium-223 chloride [13] and taxane-based chemotherapy [14]. This evidence concerns the gene AR and prostate cancer.